Next Century Growth Investors’s Standard BioTools LAB Stock Holding History

Next Century Growth Investors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-289,143	Closed	-$3.56M	–	132
2019 Q2	$3.56M	Sell	289,143 -2,750	-0.9%	-$35K	0.44%	72
2019 Q1	$3.88M	Buy	+291,893	New	+$3.08M	0.52%	74
2015 Q2	–	Sell	-1,350,994	Closed	-$56.9M	–	203
2015 Q1	$56.9M	Sell	1,350,994 -169,728	-11%	-$6.71M	2%	5
2014 Q4	$51.3M	Buy	1,520,722 +25,628	+2%	+$726K	1.85%	10
2014 Q3	$36.6M	Buy	1,495,094 +241,495	+19%	+$6.79M	1.29%	23
2014 Q2	$36.9M	Buy	1,253,599 +166,850	+15%	+$5.35M	1.18%	26
2014 Q1	$47.9M	Sell	1,086,749 -89,073	-8%	-$3.92M	1.42%	19
2013 Q4	$45.1M	Buy	1,175,822 +553,183	+89%	+$16.3M	1.25%	25
2013 Q3	$13.7M	Buy	622,639 +341,874	+122%	+$6.72M	0.39%	74
2013 Q2	$4.9M	Buy	+280,765	New	+$4.93M	0.16%	132

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Next Century Growth Investors's LAB Position: Q3 2019 in Review

Next Century Growth Investors sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 289,143 shares — an estimated $3.56M sold.

Next Century Growth Investors first reported a position in LAB in Q2 2013 and held it in 10 quarters. The position peaked at $56.9M in Q1 2015. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

Next Century Growth Investors reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
Next Century Growth Investors sold 289,143 Standard BioTools shares in Q3 2019, an estimated $3.56M.
Next Century Growth Investors first reported a position in Standard BioTools in Q2 2013 and held it in 10 quarters.
Next Century Growth Investors's Standard BioTools position peaked at $56.9M in Q1 2015.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Next Century Growth Investors's 13F filing for Q3 2019, filed 14 Nov 2019.